
Jagat R Kanwar, Kanwar R Jagat, Rakesł

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10682896/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. Expert Review of Clinical Pharmacology, 2021, 14, 715-734.	3.1	4
2	Iron bond bovine lactoferrin for the treatment of cancers and anemia associated with cancer cachexia. , 2020, , 243-254.		5
3	Rheumatoid arthritis: basic pathophysiology and role of chitosan nanoparticles in therapy. , 2020, , 481-507.		6
4	Studies on In vitro Interaction of Ampicillin and Polyalthia longifolia Leaf Ethyl Acetate Fraction (PLEAF) by Checkerboard Method Against Methicillin Resistant Staphylococcus aureus (MRSA). Current Bioactive Compounds, 2020, 16, 1049-1062.	0.5	2
5	Nanoparticles Advancing Cancer Immunotherapy. , 2019, , 283-304.		1
6	<i>In vitro</i> and <i>in vivo</i> anticandidal activities of alginate-enclosed chitosan–calcium phosphate-loaded Fe-bovine lactoferrin nanocapsules. Future Science OA, 2018, 4, FSO257.	1.9	3
7	Recent advances in nanomedicine and survivin targeting in brain cancers. Nanomedicine, 2018, 13, 105-137.	3.3	36
8	MicroRNA profiling in MDA-MB-231 human breast cancer cell exposed to the Phaleria macrocarpa (Boerl.) fruit ethyl acetate fraction (PMEAF) through Illumina Hi-Seq technologies and various in silico bioinformatics tools. Journal of Ethnopharmacology, 2018, 213, 118-131.	4.1	2
9	In vitro and in vivo toxicity assessment of alginate/eudragit S 100-enclosed chitosan–calcium phosphate-loaded iron saturated bovine lactoferrin nanocapsules (Fe-bLf NCs). Biomedicine and Pharmacotherapy, 2018, 97, 26-37.	5.6	10
10	In situ morphological assessment of apoptosis induced by Phaleria macrocarpa (Boerl.) fruit ethyl acetate fraction (PMEAF) in MDA-MB-231 cells by microscopy observation. Biomedicine and Pharmacotherapy, 2017, 87, 609-620.	5.6	5
11	Polyalthia longifolia Methanolic Leaf Extracts (PLME) induce apoptosis, cell cycle arrest and mitochondrial potential depolarization by possibly modulating the redox status in hela cells. Biomedicine and Pharmacotherapy, 2017, 89, 499-514.	5.6	19
12	Phaleria macrocarpa (Boerl.) fruit induce G 0 /G 1 and G 2 /M cell cycle arrest and apoptosis through mitochondria-mediated pathway in MDA-MB-231 human breast cancer cell. Journal of Ethnopharmacology, 2017, 201, 42-55.	4.1	20
13	Standardized Polyalthia longifolia leaf extract (PLME) inhibits cell proliferation and promotes apoptosis: The anti-cancer study with various microscopy methods. Biomedicine and Pharmacotherapy, 2017, 91, 366-377.	5.6	22
14	Argon gas plasma to decontaminate and extend shelf life of milk. Plasma Processes and Polymers, 2017, 14, 1600242.	3.0	19
15	Genetic diversity of <i>Plasmodium falciparum</i> merozoite surface proteinâ€1 (block 2), glutamateâ€rich protein and sexual stage antigen Pfs25 from Chandigarh, North India. Tropical Medicine and International Health, 2017, 22, 1590-1598.	2.3	12
16	Aged macular degeneration: current therapeutics for management and promising new drug candidates. Drug Discovery Today, 2017, 22, 1671-1679.	6.4	21
17	Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze. Frontiers in Pharmacology, 2017, 8, 223.	3.5	3
18	Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers. International Journal of Nanomedicine, 2016, 11, 1349.	6.7	10

#	Article	IF	CITATIONS
19	Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells. Frontiers in Pharmacology, 2016, 7, 81.	3.5	53
20	Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn. Frontiers in Pharmacology, 2016, 7, 226.	3.5	1
21	E-Cadherin Aptamer-Conjugated Delivery of Doxorubicin for Targeted Inhibition of Prostate Cancer Cells. Australian Journal of Chemistry, 2016, 69, 1108.	0.9	6
22	Targeting CD44, ABCG2 and CD133 markers using aptamers: in silico analysis of CD133 extracellular domain 2 and its aptamer. RSC Advances, 2016, 6, 32115-32123.	3.6	11
23	Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma. Chemico-Biological Interactions, 2016, 252, 141-149.	4.0	11
24	Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry–based imaging. Molecular Therapy - Nucleic Acids, 2016, 5, e358.	5.1	18
25	Nanotheranostic Based Iron Oxide (Fe3O4) Saturated Lactoferrin Nanocapsules for Colonic Adenocarcinoma. Journal of Biomedical Nanotechnology, 2016, 12, 1758-1773.	1.1	9
26	Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice. Scientific Reports, 2016, 6, 32062.	3.3	39
27	A Study of Gene Expression of Survivin, its Antiapoptotic Variants, and Targeting Survivin In Vitro for Therapy in Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2016, 38, e230-e242.	0.6	4
28	Multimodal iron oxide (Fe ₃ O ₄)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER ⁻ /PR ⁻ /HER2 ⁻). Nanomedicine, 2016, 11, 249-268.	3.3	34
29	Radioprotective activity of Polyalthia longifolia standardized extract against X-ray radiation injury in mice. Physica Medica, 2016, 32, 150-161.	0.7	26
30	Antiparasitic and immunomodulatory potential of oral nanocapsules encapsulated lactoferrin protein against <i>Plasmodium berghei</i> . Nanomedicine, 2016, 11, 47-62.	3.3	10
31	Exploration of the anticandidal mechanism of Cassia spectabilis in debilitating candidiasis. Journal of Traditional and Complementary Medicine, 2016, 6, 97-104.	2.7	8
32	Survivin Modulators: An Updated Patent Review (2011 - 2015). Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 152-169.	1.6	9
33	Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells. Biomicrofluidics, 2015, 9, 054110.	2.4	24
34	Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. International Journal of Nanomedicine, 2015, 10, 1019.	6.7	10
35	Neurobehavioral burden of multiple sclerosis with nanotheranostics. Neuropsychiatric Disease and Treatment, 2015, 11, 2675.	2.2	6
36	Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells. International Journal of Nanomedicine, 2015, 11, 25.	6.7	15

#	Article	IF	CITATIONS
37	Cissus quadrangularis inhibits IL-1β induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling. Drug Design, Development and Therapy, 2015, 9, 2927.	4.3	14
38	Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite–host interaction. Drug Design, Development and Therapy, 2015, 9, 3821.	4.3	20
39	Oral administration of iron-saturated bovine lactoferrin–loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. International Journal of Nanomedicine, 2015, 10, 4081.	6.7	20
40	Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions. Molecules, 2015, 20, 9703-9731.	3.8	98
41	Lactoferrin induced neuronal differentiation: A boon for brain tumours. International Journal of Developmental Neuroscience, 2015, 41, 28-36.	1.6	17
42	Blocking the Maturation of OncomiRNAs Using pri-miRNA-17â^1⁄492 Aptamer in Retinoblastoma. Nucleic Acid Therapeutics, 2015, 25, 47-52.	3.6	22
43	Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine, 2015, 10, 1289-1314.	3.3	20
44	Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine, 2015, 10, 35-55.	3.3	65
45	LNA aptamer based multi-modal, Fe 3 O 4 -saturated lactoferrin (Fe 3 O 4 -bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging. Biomaterials, 2015, 71, 84-99.	11.4	82
46	EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. Journal of Biomedical Science, 2015, 22, 4.	7.0	69
47	Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chemical Communications, 2015, 51, 6940-6943.	4.1	21
48	Nanoformulated Mutant SurR9-C84A: a Possible Key for Alzheimer's and its Associated Inflammation. Pharmaceutical Research, 2015, 32, 2787-97.	3.5	7
49	Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Advances, 2015, 5, 29008-29016.	3.6	18
50	Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer, 2015, 15, 425.	2.6	85
51	Brain targeted PLGA nanocarriers alleviating amyloid-Î' expression and preserving basal survivin in degenerating mice model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2423-2431.	3.8	3
52	Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras. Nucleic Acid Therapeutics, 2015, 25, 317-322.	3.6	23
53	Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discovery Today, 2015, 20, 578-587.	6.4	68
54	EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer. PLoS ONE, 2015, 10, e0132407.	2.5	35

#	Article	IF	CITATIONS
55	Nanoformulated cell-penetrating survivin mutant and its dual actions. International Journal of Nanomedicine, 2014, 9, 3279.	6.7	11
56	Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers. Nanomedicine, 2014, 9, 819-837.	3.3	21
57	Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discovery Today, 2014, 19, 1309-1321.	6.4	33
58	A strain-promoted alkyne–azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer–fluorescent conjugate for imaging of cancer cells. Chemical Communications, 2014, 50, 11810-11813.	4.1	21
59	Fabrication of Boron Nitride Nanotube–Gold Nanoparticle Hybrids Using Pulsed Plasma in Liquid. Langmuir, 2014, 30, 10712-10720.	3.5	17
60	The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials, 2014, 35, 7522-7534.	11.4	61
61	Identification of Unprecedented Anticancer Properties of High Molecular Weight Biomacromolecular Complex Containing Bovine Lactoferrin (HMW-bLf). PLoS ONE, 2014, 9, e106568.	2.5	24
62	Survivin Signaling in Clinical Oncology: A Multifaceted Dragon. Medicinal Research Reviews, 2013, 33, 765-789.	10.5	79
63	Generating different profiles of gradient concentrations inside a gel-filled chamber: design and simulation. Microsystem Technologies, 2013, 19, 623-628.	2.0	3
64	Natural antioxidant biomolecules promises future nanomedicine based therapy for cataract. Colloids and Surfaces B: Biointerfaces, 2013, 112, 554-562.	5.0	41
65	Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discovery Today, 2013, 18, 1292-1300.	6.4	57
66	Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE, 2013, 8, e62289.	2.5	47
67	Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer. Protein and Peptide Letters, 2013, 20, 450-458 Evaluation of the Genotoxic Potential against Amml:math	0.9	31
68	xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"> <mml:msub><mml:mrow><mml:mtext>H</mml:mtext></mml:mrow><mml:mrow><mml:mrow mathvariant="bold">2</mml:mrow </mml:mrow></mml:msub> <mml:msub><mml:mrow><mml:mtext>Omathvariant="bold">2</mml:mtext></mml:mrow></mml:msub> -Radical-Mediated DNA Damage	ıtext .2 <td>ml:#8:ow><mr< td=""></mr<></td>	ml: #8 :ow> <mr< td=""></mr<>
69	and Acute Oral Toxicity of Standardized Extract of <i>Polyalthia longifolia</i> Leaf. Evidence-based Co RNAi Mediated Tiam1 Gene Knockdown Inhibits Invasion of Retinoblastoma. PLoS ONE, 2013, 8, e70422.	2.5	25
70	Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer. Protein and Peptide Letters, 2013, 20, 450-458.	0.9	23
71	Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in Cancerous Colon Perfusion Rat Model. Journal of Cancer Science & Therapy, 2013, 5, 313-319.	1.7	30
72	Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?. Nanomedicine, 2012, 7, 899-916.	3.3	22

#	Article	IF	CITATIONS
73	Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide. Anti-Cancer Drugs, 2012, 23, 471-482.	1.4	13
74	Neurological disorders and therapeutics targeted to surmount the blood–brain barrier. International Journal of Nanomedicine, 2012, 7, 3259.	6.7	84
75	Novel nanoplatform for oral delivery of anti-cancer biomacromolecules. International Journal of Nanotechnology, 2012, 9, 942.	0.2	10
76	Cancer Targeted Nanoparticles Specifically Induce Apoptosis in Cancer Cells and Spare Normal Cells. Australian Journal of Chemistry, 2012, 65, 5.	0.9	18
77	Nanotechnology based platforms for survivin targeted drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 1083-1092.	5.0	12
78	Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages. Nanomedicine, 2012, 7, 735-749.	3.3	24
79	Novel alginate-enclosed chitosan–calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine, 2012, 7, 1521-1550.	3.3	95
80	Gradient Generating Microfluidic Devices for Cell Cultivation. Procedia Engineering, 2012, 29, 1740-1744.	1.2	5
81	The Antimicrobial Efficacy of Elaeis guineensis: Characterization, in Vitro and in Vivo Studies. Molecules, 2012, 17, 4860-4877.	3.8	32
82	Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 399-414.	3.3	111
83	Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Molecular Vision, 2012, 18, 2783-95.	1.1	51
84	The role of nanomedicine in cell based therapeutics in cancer and inflammation. International Journal of Molecular and Cellular Medicine, 2012, 1, 133-44.	1.1	13
85	Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine, 2011, 6, 701-714.	3.3	13
86	Chimeric aptamers in cancer cell-targeted drug delivery. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 459-477.	5.2	118
87	Lactoferrin and cancer in different cancer models. Frontiers in Bioscience - Scholar, 2011, S3, 1080.	2.1	61
88	Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy. Current Drug Delivery, 2011, 8, 45-58.	1.6	96
89	Mitomycin C: a promising agent for the treatment of canine corneal scarring. Veterinary Ophthalmology, 2011, 14, 304-312.	1.0	18
90	Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. Journal of Neuroimmunology, 2011, 233, 18-28.	2.3	14

Jagat R Kanwar, Kanwar R

#	Article	IF	CITATIONS
91	Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discovery Today, 2011, 16, 188-202.	6.4	33
92	Targeting survivin in cancer: the cell-signalling perspective. Drug Discovery Today, 2011, 16, 485-494.	6.4	110
93	Structure and properties of biomedical films prepared from aqueous and acidic silk fibroin solutions. Journal of Biomedical Materials Research - Part A, 2011, 97A, 37-45.	4.0	67
94	Molecular weight and secondary structure change in eri silk during alkali degumming and powdering. Journal of Applied Polymer Science, 2011, 119, 1339-1347.	2.6	45
95	Effect of Selenium-Saturated Bovine Lactoferrin (Se-bLF) on Antioxidant Enzyme Activities in Human Gut Epithelial Cells Under Oxidative Stress. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 762-771.	1.7	20
96	Survivin Mutant Protects Differentiated Dopaminergic SK-N-SH Cells Against Oxidative Stress. PLoS ONE, 2011, 6, e15865.	2.5	22
97	Antioxidant Enzyme Activities of Iron-Saturated Bovine Lactoferrin (Fe-bLf) in Human Gut Epithelial Cells Under Oxidative Stress. Medicinal Chemistry, 2011, 7, 224-230.	1.5	37
98	Survivin: A target from brain cancer to neurodegenerative disease. Critical Reviews in Biochemistry and Molecular Biology, 2010, 45, 535-554.	5.2	46
99	Proliferative and protective effects of SurR9-C84A on differentiated neural cells. Journal of Neuroimmunology, 2010, 227, 120-132.	2.3	27
100	A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell International, 2010, 10, 36.	4.1	48
101	MicroRNA in human cancer and chronic inflammatory diseases. Frontiers in Bioscience - Scholar, 2010, S2, 1113-1126.	2.1	45
102	Therapeutic Effects of Matrine on Primary and Metastatic Breast Cancer. The American Journal of Chinese Medicine, 2010, 38, 1115-1130.	3.8	58
103	Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Molecular Cancer, 2010, 9, 77.	19.2	47
104	Targeting survivin in cancer: patent review. Expert Opinion on Therapeutic Patents, 2010, 20, 1723-1737.	5.0	47
105	Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine, 2010, 5, 1435-1445.	3.3	38
106	Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice. Cancer Investigation, 2010, 28, 74-84.	1.3	47
107	Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System. Current Neuropharmacology, 2010, 8, 268-275.	2.9	10
108	Applications of Nanomedicine in Antibacterial Medical Therapeutics and Diagnostics~!2009-08-26~!2009-11-25~!2010-02-24~!. The Open Tropical Medicine Journal, 2010, 3, 1-9.	0.3	22

Jagat R Kanwar, Kanwar R

#	Article	IF	CITATIONS
109	Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders. Current Medicinal Chemistry, 2009, 16, 2373-2394.	2.4	208
110	Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal. BMC Immunology, 2009, 10, 7.	2.2	44
111	Molecular and Biotechnological Advances in Milk Proteins in Relation to Human Health. Current Protein and Peptide Science, 2009, 10, 308-338.	1.4	75
112	â€~Ironâ€saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunology and Cell Biology, 2008, 86, 277-288.	2.3	86
113	A pseudosymmetric cell adhesion regulatory domain in the β7 tail of the integrin α4β7 that interacts with focal adhesion kinase and src. European Journal of Immunology, 2006, 36, 2203-2214.	2.9	13
114	Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. International Journal of Cancer, 2006, 118, 1823-1830.	5.1	54
115	Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Therapy, 2005, 12, 35-45.	4.6	28
116	Anti-Inflammatory Immunotherapy for Multiple Sclerosis/Experimental Autoimmune Encephalomyelitis (EAE) Disease. Current Medicinal Chemistry, 2005, 12, 2947-2962.	2.4	48
117	Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain, 2004, 127, 1313-1331.	7.6	105
118	Bioassay detects soluble MAdCAMâ€l in body fluids. Immunology and Cell Biology, 2004, 82, 400-409.	2.3	15
119	Mucosal vascular addressin cell adhesion moleculeâ€1 is expressed outside the endothelial lineage on fibroblasts and melanoma cells. Immunology and Cell Biology, 2003, 81, 320-327.	2.3	9
120	Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Therapy, 2003, 10, 468-476.	4.6	20
121	??7 integrins contribute to skin graft rejection. Transplantation, 2002, 74, 1202-1203.	1.0	3
122	Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Therapy, 2001, 8, 719-727.	4.6	30
123	Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ. Cancer Gene Therapy, 2001, 8, 974-981.	4.6	12
124	Temporal Expression of Heat Shock Proteins 60 and 70 at Lesion-Prone Sites During Atherogenesis in ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1991-1997.	2.4	85
125	Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy. Journal of the National Cancer Institute, 2001, 93, 1541-1552.	6.3	160
126	Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunology and Cell Biology, 2000, 78, 641-645.	2.3	58

#	Article	IF	CITATIONS
127	β7 integrins contribute to demyelinating disease of the central nervous system. Journal of Neuroimmunology, 2000, 103, 146-152.	2.3	87
128	Biochemical and nutritional characteristics of non-conventional protein sources. Journal of the Science of Food and Agriculture, 1991, 55, 141-151.	3.5	5